PL1632232T3 - Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu - Google Patents

Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu

Info

Publication number: PL1632232T3
Authority: PL; Poland
Prior art keywords: amino; cyanoethenyl; benzonitrile; dimethylphenyl; pyrimidinyl
Prior art date: 2004-09-02

Application number

PL05108086T

Other languages

English (en)

Other versions

PL1632232T6 (pl

Inventor

Paul Theodoor Agnes Stevens

Jozef Peeters

Roger Petrus Gerebern Vandecruys

Alfred Elisabeth Stappers

Alex Herman Copmans

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-02

Filing date

2005-09-02

Publication date

2011-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34940340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1632232(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-09-02 Priority claimed from MYPI20043578A external-priority patent/MY169670A/en

2005-09-02 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2005-09-02 Priority claimed from EP05108086.9A external-priority patent/EP1632232B3/en

2011-10-31 Publication of PL1632232T3 publication Critical patent/PL1632232T3/pl

2022-06-27 Publication of PL1632232T6 publication Critical patent/PL1632232T6/pl

Links

JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 title 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 2
150000003839 salts Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PL05108086T 2004-09-02 2005-09-02 Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu PL1632232T6 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
MYPI20043578A MY169670A (en)	2003-09-03	2004-09-02	Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en)	2003-09-03	2004-09-03	Combinations of a pyrimidine containing nnrti with rt inhibitors
EP05101467		2005-02-25
EP05108086.9A EP1632232B3 (en)	2004-09-02	2005-09-02	Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile

Publications (2)

Publication Number	Publication Date
PL1632232T3 true PL1632232T3 (pl)	2011-10-31
PL1632232T6 PL1632232T6 (pl)	2022-06-27

Family

ID=34940340

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05108086T PL1632232T6 (pl)	2004-09-02	2005-09-02	Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu

Country Status (5)

Country	Link
KR (1)	KR101284361B1 (pl)
AU (1)	AU2005279158C1 (pl)
CA (1)	CA2577288C (pl)
PL (1)	PL1632232T6 (pl)
WO (1)	WO2006024668A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
BRPI0707179A2 (pt) *	2006-01-20	2011-04-26	Tibotec Pharm Ltd	tratamento de longo termo de infecção por hiv
CL2008000746A1 (es)	2007-03-14	2008-09-22	Tibotec Pharm Ltd	Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
BRPI0811732A2 (pt) *	2007-06-08	2014-11-18	Boehring Ingelheim Internat Gmbh	Formulação de liberação prolongada de nevirapina
SI2175857T1 (sl) *	2007-07-12	2014-01-31	Janssen R&D Ireland	Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila
PE20121524A1 (es)	2010-01-27	2012-12-03	Viiv Healthcare Co	Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
SG10201509521WA (en)	2010-11-19	2015-12-30	Gilead Sciences Inc	Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (en)	2011-03-17	2012-09-20	Teva Pharmaceutical Industries Ltd.	Solid state forms of rilpivirine base, and rilipivirine salts
WO2013038425A1 (en) *	2011-09-16	2013-03-21	Hetero Research Foundation	Rilpivirine hydrochloride
WO2013087794A1 (en) *	2011-12-14	2013-06-20	Sandoz Ag	Polymorph of rilpivirine hydrochloride and its use as antiviral
EP2604593A1 (en) *	2011-12-14	2013-06-19	Sandoz AG	Polymorph of Rilpivirine hydrochloride and its use as antiviral
WO2018077815A1 (en) *	2016-10-24	2018-05-03	Janssen Sciences Ireland Uc	Dispersible compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY169670A (en) *	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) *	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
KR101140785B1 (ko) *	2002-08-09	2012-05-03	얀센 파마슈티카 엔.브이.	4-〔〔4-〔〔4-（2-시아노에테닐）-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법

2005
- 2005-09-02 CA CA2577288A patent/CA2577288C/en not_active Expired - Lifetime
- 2005-09-02 WO PCT/EP2005/054342 patent/WO2006024668A1/en not_active Ceased
- 2005-09-02 PL PL05108086T patent/PL1632232T6/pl unknown
- 2005-09-02 AU AU2005279158A patent/AU2005279158C1/en active Active
- 2005-09-02 KR KR1020077006837A patent/KR101284361B1/ko not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO2006024668A1 (en)	2006-03-09
AU2005279158B2 (en)	2010-06-17
CA2577288A1 (en)	2006-03-09
KR101284361B1 (ko)	2013-07-15
KR20070074555A (ko)	2007-07-12
CA2577288C (en)	2010-11-30
PL1632232T6 (pl)	2022-06-27
AU2005279158C1 (en)	2010-12-16
AU2005279158A1 (en)	2006-03-09

Publication	Publication Date	Title
LTC1632232I2 (lt)	2024-09-10	4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
PL373679A1 (pl)	2005-09-05	Sposoby otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
IL202363A0 (en)	2010-06-30	Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
NO2014030I1 (no)	2015-01-05	(E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.
TWI341310B (en)	2011-05-01	Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
IS2689B (is)	2010-10-15	Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts
DK1682536T3 (da)	2013-05-06	Fremgangsmåde til fremstilling af calciumsaltet af rosuvastatin (e)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-ensyre og krystallinske mellemprodukter deraf
PL1632232T3 (pl)	2011-10-31	Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
AP2487A (en)	2012-10-03	Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
AP2296A (en)	2011-10-31	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile.
IL181649A0 (en)	2007-07-04	Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino) benzonitrile